• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    86.81 +2.42 (+2.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 507,327
    Open 83.96
    Bid (Size) 83.00 (100)
    Ask (Size) 92.00 (100)
    Prev. Close 84.39
    Today's Range 83.96 - 87.61
    52wk Range 55.31 - 122.20
    Shares Outstanding 66,684,077
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
    Via MarketMinute

    Performance

    YTD
    -17.3%
    -17.3%
    1 Month
    -0.7%
    -0.7%
    3 Month
    -17.2%
    -17.2%
    6 Month
    -13.9%
    -13.9%
    1 Year
    +44.3%
    +44.3%

    More News

    Read More
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗
    Via Chartmill
    RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
    Via Stocktwits
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Rhythm Pharmaceuticals Announces Changes to Board of Directors
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharma (RYTM) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Via The Motley Fool
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This High-Flying Growth Stock Is Hiding in Plain Sight ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
    Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
    What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 86.81
    When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 04/13/26 04:00 PM ET
    What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 5.79B
    How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.